ZYNTEGLO Sales Forecast, and Market Size Analysis - 2034
상품코드:1938038
리서치사:DelveInsight
발행일:On Demand Report
페이지 정보:영문 30 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
ZYNTEGLO의 주요 성장 촉진요인
1. 시장 점유율 확대 및 신규 환자 증가
ZYNTEGLO는 수혈 의존성 베타살라세미아(TDT) 시장에서 평생 수혈과 철 킬레이트 요법을 대체하는 단일 투여 유전자 치료로서 꾸준히 인지도를 높이고 있습니다.
치료 센터의 가동 확대와 수혈 불필요한 상태의 지속성을 뒷받침하는 장기 데이터로 신규 환자의 치료 개시가 증가하고 있습니다.
bluebird bio의 환자 접근 프로그램, 상환 파트너십, 의사 교육 활동은 적격 환자의 채용을 가속화하고 있습니다.
2. 중요한 적응증으로 확대
수혈 의존성 베타살라세미아(TDT) : ZYNTEGLO는 TDT 환자에게 적용이 승인되었으며, 기능적인 헤모글로빈의 지속적인 생산을 가능하게 하고, 수혈의 필요성을 제거하거나 상당히 완화시킵니다.
중증 유전형 : 이식을 위한 적합성 기증자가 없는 비 B0/B0 유전형 환자에서 높은 채용률.
기능적 치유의 가능성 : 이 치료법은 렌티바이러스를 이용한 유전자 도입을 통해 근본적인 유전자 결손을 수정하고 장기적인 질병 변형 효과를 제공합니다.
파이프라인 학습 : 제조 및 컨디셔닝을 최적화하는 프로그램은 향후 광범위한 사용을 지원할 수 있습니다.
3. 지리적 확대
ZYNTEGLO는 미국과 유럽 연합에서 승인되었으며 주요 이식 거점에 치료 센터가 설치되어 있습니다.
유럽과 중동은 TDT의 이환율이 높고 사라세미아 치료 네트워크가 확립되어 성장이 기대되는 지역입니다.
bluebird bio는 치료 접근을 지원하기 위해 허가 치료 시설의 확충과 상환 경로의 정비를 계속 진행하고 있습니다.
4. 신규 적응증 승인
ZYNTEGLO는 미국 FDA에서 TDT에 대한 승인을 받았으며 헤모글로빈병에 대한 유전자 치료에서 중요한 이정표가 되었습니다.
유럽 규제 당국의 승인으로 상업 개발이 더욱 확대되었습니다.
진행 중인 규제 당국과의 협의는 미래에 대상 연령대 및 유전형 하위군의 확대를 기대할 것입니다.
5. TDT의 강력한 수량 추이
만성 수혈 요법을 대체하는 근치적 치료법에 대한 수요가 높아지는 가운데, TDT는 계속해서 제1 촉진요인이 되고 있습니다.
임상 데이터 및 실제 세계 데이터는 지속적인 수혈 불필요한 상태와 삶의 질 향상을 보여줍니다.
환자 지원 활동 및 소개 네트워크의 확대로 치료에 대한 도입이 가속화되고 있습니다.
6. 경쟁 차별화 및 시장 동향
ZYNTEGLO는 평생 수혈이나 철 킬레이트 요법과는 달리, 단회 투여로 근치의 가능성을 지닌 유전자 치료인 점이 차별화 요인입니다.
개인화된 세포 요법은 정밀의료 및 유전자 기반 치료법의 동향을 따릅니다.
성과에 근거한 보상 모델에 대한 보험자의 관심이 높아짐에 따라 접근을 지원합니다.
실제 임상 지속성 데이터에 대한 의존도가 높아짐에 따라 임상의 및 보험자의 신뢰성이 향상되었습니다.
ZYNTEGLO의 최근 발전
최근 bluebird bio에 의한 발표는 미국과 유럽에서 ZYNTEGLO의 상업 이용 확대, 치료 시설 증가 및 수혈 의존성으로부터의 지속적인 이탈을 보여주는 양호한 장기 추적 데이터를 강조했습니다. 이 회사는 또한 제조의 확장성 및 환자 접근 프로그램 진행, 그리고 상환 및 치료 물류를 지원하는 전략적 제휴에 대해서도 언급하고 있습니다. 이러한 발전은 수혈 의존성 베타 살라세미아에 대한 주요 유전자 치료법으로서 ZYNTEGLO의 지위를 확고히 하고 있습니다.
이 보고서는 ZYNTEGLO의 주요 7개 시장(미국, 독일, 프랑스, 이탈리아, 스페인, 영국, 일본)에 대한 조사 분석을 통해 각국 시장 규모 및 예측, 연구 개발 활동, 경쟁 구도 등의 정보를 제공합니다.
목차
제1장 보고서 개요
제2장 베타살라세미아 및 겸상 적혈구 빈혈증과 같은 승인된 적응증에서 ZYNTEGLO 개요
제품 상세
ZYNTEGLO의 임상 개발
ZYNTEGLO의 임상시험
ZYNTEGLO의 임상시험 정보
안전성 및 유효성
기타 개발 활동
제품 프로파일
제3장 ZYNTEGLO 경쟁 구도(출시 끝난 치료법)
제4장 경쟁 구도(후기 단계의 ZYNTEGLO 치료제)
제5장 ZYNTEGLO 시장 평가
승인된 적응증에서 ZYNTEGLO 시장 전망
주요 7개 시장 분석
주요 7시장 ZYNTEGLO 시장 규모(승인된 적응증)
각국 시장 분석
미국 ZYNTEGLO 시장 규모(승인된 적응증)
독일 ZYNTEGLO 시장 규모(승인된 적응증)
영국 ZYNTEGLO 시장 규모(승인된 적응증)
제6장 ZYNTEGLO의 SWOT 분석
제7장 애널리스트의 견해
제8장 부록
제9장 DelveInsight의 서비스 내용
제10장 면책사항
제11장 DelveInsight 정보
제12장 보고서 구매 옵션
AJY
영문 목차
영문목차
Key Factors Driving ZYNTEGLO Growth
1. Market Share Gains and New Patient Starts
ZYNTEGLO is gaining traction in the transfusion-dependent beta-thalassemia (TDT) market as a one-time gene therapy alternative to lifelong transfusions and iron chelation.
New patient starts are increasing as treatment center activation expands and long-term data reinforce the durability of transfusion independence.
Bluebird bio's patient access programs, reimbursement partnerships, and physician education efforts are accelerating adoption in eligible patients.
2. Expansion Across Key Indications
Transfusion-Dependent Beta-Thalassemia (TDT): ZYNTEGLO is approved for patients with TDT, enabling sustained production of functional hemoglobin and eliminating or significantly reducing transfusion needs.
Severe Genotypes: Strong uptake in patients with non-B0/B0 genotypes who lack matched donors for transplant.
Functional Cure Potential: The therapy addresses the underlying genetic defect through lentiviral gene addition, offering long-term disease modification.
Pipeline Learnings: Manufacturing and conditioning optimization programs may support broader future use.
3. Geographic Expansion
ZYNTEGLO is approved in the US and European Union, with treatment centers being activated across major transplant hubs.
Europe and the Middle East represent strong growth regions due to higher prevalence of TDT and established thalassemia care networks.
Bluebird bio continues to expand authorized treatment centers and reimbursement pathways to support access.
4. New Indication Approvals
ZYNTEGLO received US FDA approval for TDT, marking a major milestone in gene therapy for hemoglobinopathies.
Regulatory approvals in Europe further broadened its commercial footprint.
Ongoing regulatory discussions may support expanded age groups and genotype subsets in the future.
5. Strong TDT Volume Momentum
TDT remains the primary growth driver, with increasing demand for curative alternatives to chronic transfusion regimens.
Clinical and real-world data demonstrate durable transfusion independence and improved quality of life.
Rising patient advocacy and referral networks are accelerating treatment uptake.
6. Competitive Differentiation and Market Trends
One-time, potentially curative gene therapy differentiates ZYNTEGLO from lifelong transfusions and iron chelation.
Personalized cell therapy aligns with trends toward precision medicine and gene-based cures.
Growing payer interest in outcomes-based reimbursement models is supporting access.
Increasing reliance on real-world durability data is strengthening confidence among clinicians and payers.
ZYNTEGLO Recent Developments
Recent announcements from bluebird bio have highlighted expanded commercial availability of ZYNTEGLO in the US and Europe, growing treatment center activation, and positive long-term follow-up data demonstrating sustained transfusion independence. The company has also emphasized progress in manufacturing scalability and patient access programs, along with strategic partnerships to support reimbursement and treatment logistics. These developments reinforce ZYNTEGLO's position as a leading gene therapy for transfusion-dependent beta-thalassemia.
"ZYNTEGLO Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of ZYNTEGLO for approved indication like Beta-thalassaemia and Sickle cell anaemia in the 7MM. A detailed picture of ZYNTEGLO's existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the ZYNTEGLO for approved indications. The ZYNTEGLO market report provides insights about ZYNTEGLO's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current ZYNTEGLO performance, future market assessments inclusive of the ZYNTEGLO market forecast analysis for approved indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of ZYNTEGLO sales forecasts, along with factors driving its market.
ZYNTEGLO Drug Summary
ZYNTEGLO (betibeglogene autotemcel) is an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of adult and pediatric patients with B-thalassemia who require regular red blood cell (RBC) transfusions, including those 12 years and older with transfusion-dependent B-thalassemia (TDT) for whom hematopoietic stem cell transplantation is appropriate but an HLA-matched related donor is unavailable. It involves ex vivo transduction of the patient's own CD34+ hematopoietic stem cells (HSCs) with a lentiviral vector (BB305 LVV) encoding a functional modified B-globin gene (BA-T87Q-globin), which integrates into the genome to produce hemoglobin A T87Q (HbAT87Q), correcting the a/B-globin imbalance, enabling functional hemoglobin production in erythroid lineage cells post-engraftment, and achieving transfusion independence in a significant proportion of patients. Administered as a one-time intravenous infusion of cryopreserved cells (minimum dose >=3 X 10^6 CD34+ cells/kg) following myeloablative conditioning, mobilization, apheresis, and manufacturing, ZYNTEGLO is a personalized therapy delivered in qualified treatment centers with monitoring for risks like hematologic malignancy and genotoxicity. The report provides ZYNTEGLO's sales, growth barriers and drivers, post usage and approvals in multiple indications.
Scope of the ZYNTEGLO Market Report
The report provides insights into:
A comprehensive product overview including the ZYNTEGLO MoA, description, dosage and administration, research and development activities in approved indication like Beta-thalassaemia and Sickle cell anaemia.
Elaborated details on ZYNTEGLO regulatory milestones and other development activities have been provided in ZYNTEGLO market report.
The report also highlights ZYNTEGLO's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan.
The ZYNTEGLO market report also covers the patents information, generic entry and impact on cost cut.
The ZYNTEGLO market report contains current and forecasted ZYNTEGLO sales for approved indications till 2034.
Comprehensive coverage of the late-stage emerging therapies for respective indications.
The ZYNTEGLO market report also features the SWOT analysis with analyst views for ZYNTEGLO in approved indications.
Methodology:
The ZYNTEGLO market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
ZYNTEGLO Analytical Perspective by DelveInsight
In-depth ZYNTEGLO Market Assessment
This ZYNTEGLO sales market forecast report provides a detailed market assessment of ZYNTEGLO for approved indication like Beta-thalassaemia and Sickle cell anaemia in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted ZYNTEGLO sales data uptil 2034.
ZYNTEGLO Clinical Assessment
The ZYNTEGLO market report provides the clinical trials information of ZYNTEGLO for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.
ZYNTEGLO Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
ZYNTEGLO Market Potential & Revenue Forecast
Projected market size for the ZYNTEGLO and its key indications
Commercial partnerships, licensing deals, and M&A activity
ZYNTEGLO Clinical Differentiation
ZYNTEGLO Efficacy & safety advantages over existing drugs
ZYNTEGLO Unique selling points
ZYNTEGLO Market Report Highlights
In the coming years, the ZYNTEGLO market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
The ZYNTEGLO companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ZYNTEGLO's dominance.
Other emerging products for Beta-thalassaemia and Sickle cell anaemia are expected to give tough market competition to ZYNTEGLO and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ZYNTEGLO in approved indications.
Analyse ZYNTEGLO cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
Our in-depth analysis of the forecasted ZYNTEGLO sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of ZYNTEGLO in approved indications.
Key Questions:
What is the class of therapy, route of administration and mechanism of action of ZYNTEGLO? How strong is ZYNTEGLO's clinical and commercial performance?
What is ZYNTEGLO's clinical trial status in each individual indications such as Beta-thalassaemia and Sickle cell anaemia and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ZYNTEGLO Manufacturers?
What are the key designations that have been granted to ZYNTEGLO for approved indications? How are they going to impact ZYNTEGLO's penetration in various geographies?
What is the current and forecasted ZYNTEGLO market scenario for approved indications? What are the key assumptions behind the forecast?
What are the current and forecasted sales of ZYNTEGLO in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What are the other emerging products available and how are these giving competition to ZYNTEGLO for approved indications?
Which are the late-stage emerging therapies under development for the treatment of approved indications?
How cost-effective is ZYNTEGLO? What is the duration of therapy and what are the geographical variations in cost per patient?
Table of Contents
1. Report Introduction
2. ZYNTEGLO Overview in approved indications like Beta-thalassaemia and Sickle cell anaemia
